David Elsley
Vermogen: 2 M $ op 31-05-2026
Vermogen: 2 M $ op 31-05-2026
David G.
Elsley was the founder of Vasogen, Inc., founded in 1990, where the title held was Director from 1990 to 2009.
Mr. Elsley is the founder of Cardiol Therapeutics, Inc., founded in 2017, holding the titles of President, Chief Executive Officer & Director since 2017.
Mr. Elsley completed an MBA degree at Richard Ivey School of Business.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-12-2025 | 1.344.500 ( 1,2% ) | 2 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Oprichter | 19-01-2017 |
| Bedrijven | Functie | Einde |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Oprichter | 23-10-2009 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
Richard Ivey School of Business
Richard Ivey School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau